Clinical Trials Browser

Phase 3 × 130-nm albumin-bound paclitaxel × Clear all

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT06767527 2026-03-16

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT07060807 2026-03-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Phase 3 Recruiting

Breast Neoplasms

NCT06312176 2026-03-13

MK-2870-010

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT06422143 2026-03-13

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06841354 2026-03-13

TroFuse-011

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT04205812 2026-03-10

POD1UM-304

Phase 3 Active not recruiting

583 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04083235 2026-03-09

NAPOLI 3

Phase 3 Completed

770 enrolled 13 charts 1 FDA

Gastrointestinal

Metastatic Adenocarcinoma of the Pancreas

NCT04222972 2026-03-05

AcceleRET-Lung

Phase 3 Terminated

223 enrolled 18 charts

Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06018337 2026-03-05

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Phase 3 Active not recruiting

Breast Neoplasms

NCT04494425 2026-03-04

DB-06

Phase 3 Active not recruiting

866 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT06608927 2026-02-27

PRISM-1

Phase 3 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07436741 2026-02-27

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Phase 3 Not yet recruiting

Gastrointestinal

Pancreatic cancer, adult

NCT03774732 2026-02-25

NIRVANA-LUNG

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03976362 2026-02-25

KEYLYNK-008

Phase 3 Completed

851 enrolled 25 charts

Carcinoma

NCT06692738 2026-02-25

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06998940 2026-02-20

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05226598 2026-02-05

MK-7684A-007

Phase 3 Completed

739 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT06958328 2026-02-02

LAP100

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05502237 2026-01-30

STAR-121

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05374512 2026-01-27

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06279364 2026-01-27

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT03456063 2026-01-22

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Phase 3 Completed

Non-Small-Cell Lung

NCT05624996 2026-01-14

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT06132958 2026-01-09

TroFuse-005

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT04148911 2025-12-26

EL1SSAR

Phase 3 Completed

184 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT07272109 2025-12-15

PTCA199-16

Phase 3 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06625320 2025-12-12

RASolute 302

Phase 3 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07071337 2025-12-11

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Phase 3 Recruiting

Breast Neoplasms

NCT03257033 2025-11-14

TIGeR-PaC

Phase 3 Recruiting

Gastrointestinal

Locally Advanced Pancreatic Cancer

NCT06212752 2025-11-12

MK-3475A-D77

Phase 3 Active not recruiting

39 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03520686 2025-10-16

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase 3 Active not recruiting

557 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT05840211 2025-10-03

ASCENT-07

Phase 3 Active not recruiting

Breast Neoplasms

NCT07079228 2025-09-23

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05722015 2025-09-11

MK-3475A-D77

Phase 3 Active not recruiting

377 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02514681 2025-09-10

PRECIOUS

Phase 3 Completed

Breast Neoplasms

NCT07155629 2025-09-04

LEFT-PANC

Phase 3 Not yet recruiting

Gastrointestinal

Pancreatic Cancer Resectable

NCT06018883 2025-08-07

PTCA199-3

Phase 3 Active not recruiting

Classical hematology

Anemia

NCT06250972 2025-08-07

PTCA199-11

Phase 3 Recruiting

Gastrointestinal

Pancreatic Adenocarcinoma

NCT07062263 2025-07-14

TAB-2

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT04085276 2025-06-11

TORCHLIGHT

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT03750669 2025-05-13

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

Phase 3 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT05257408 2025-04-16

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Phase 3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT06419621 2025-03-12

PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT04956692 2024-12-03

MK-3475-A86

Phase 3 Active not recruiting

531 enrolled 18 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02819518 2024-11-27

KEYNOTE-355

Phase 3 Completed

882 enrolled 41 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02775435 2024-10-08

KEYNOTE-407

Phase 3 Completed

559 enrolled 18 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

Phase 3 Active not recruiting

Breast Neoplasms